CD22/CD19 CAR-T cell immunotherapy Clinical Trials

2 actively recruiting trials

▲ +1 trial since August 2026

Pipeline

Phase 2: 2

Top Sponsors

Liping Dou2

Indications

Lymphoma2
Cancer2

Other2 trials

CD19/CD22 CAR-T Consolidation in R/R Aggressive B-Cell Lymphoma After Second-Line Therapy

Phase 2

CD19/CD22 CAR-T as First-line Consolidation in Follicular Lymphoma

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.